EMA Authorised: Kanjinti (trastuzumab) — Amgen Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Kanjinti (trastuzumab) by Amgen Europe B.V. for gastric and breast cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• KANJINTI (TRASTUZUMAB-ANNS)

Snippet

Status: Authorised. Therapeutic area: Stomach Neoplasms;Breast Neoplasms. MAH: Amgen Europe B.V.. Decision date: 13/05/2025